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THE AMERICA INSOMNIA SURVEY (AIS): AN EPIDEMIOLOGY STUDY 
OF INSOMNIA PREVALENCE AND BURDEN IN A REPRESENTATIVE 
POPULATION
Kessler RC1, Coulouvrat C2, Hajak G3, Roth T4, Sampson N1, Shillington AC5, 
`Stephenson JJ6, Walsh J7
1Harvard Medical School, Boston, MA, USA, 2Sanoﬁ-Aventis Group, Paris, France, 3University 
of Regensburg, Regensburg, Germany, 4Henry Ford Hospital, Detroit, MI, USA, 5EPI-Q Inc, 
Oak Brook, IL, USA, 6HealthCore, Inc., Wilmington, PA, USA, 7St. Luke’s Hospital, 
Chesterﬁeld, MO, USA
OBJECTIVES: To investigate the association between insomnia, health care utiliza-
tion and cost in a representative population. METHODS: The America Insomnia 
Survey (AIS) is an epidemiology study of insomnia prevalence and burden of illness 
in the US. The Brief Insomnia Questionnaire (BIQ), a fully structured diagnostic 
interview, was administered to a representative sample of subscribers from 14 geo-
graphically dispersed US health plans in the HealthCore Integrated Research Data-
base. The aim was to investigate associations between insomnia and relevant 
outcomes, (daytime impairment, accidents, injuries, lost productivity, health care 
consumption). Respondents were medical and pharmacy beneﬁt eligible and had 
minimum12 months continuous enrollment prior to the survey date. Survey and 
administrative claims data were merged. Data were analyzed using SAS Genmod 
with log link and gamma distribution for costs adjusting for Deyo-Charlson Index 
score. Respondents were classiﬁed as ‘any insomnia (AI)’ and ‘no insomnia (NI)’ 
with ‘any insomnia’ deﬁned as meeting criteria for any of 3 nosologic systems (DSM, 
ICD, Research Diagnostic Criteria [RDC]). RESULTS: Of 10,094 respondents, 
insomnia prevalence is 23.6%. Of insomnia subtypes alone and in combination, 
waking in the night is most prevalent (61.5%), followed by waking too early (52.1%), 
difﬁculty falling asleep (38.0%) and non-restorative sleep (6.2%). Compared to NI, 
AI are more often female (58.1% vs. 49.6%; p < 0.0001) and younger (45.1 ± 16.6 
vs. 46.6 ± 17.6; p = 0.001). Preliminary claims analysis suggests within 12 months 
prior to the survey, AI had signiﬁcantly higher all-cause medical costs than NI 
respondents ($4,830 vs. $3,714, respectively; p < 0.0001). All-cause pharmacy costs 
were signiﬁcantly higher for AI than NI ($1,186 vs. $959, respectively; p < 0.0001). 
CONCLUSIONS: The prevalence of insomnia is higher than previously thought with 
sleep maintenance as the most important symptom. Insomnia accounts for signiﬁcant 
health care costs in the US.
PND11
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OBJECTIVES: Assess the impact on health care utilization and expenditures of 
treating patients early with disease modifying therapy (DMT: interferons or glat-
iramer acetate) rather than delaying until patients have met full diagnostic criteria 
of multiple sclerosis (MS). METHODS: A retrospective cohort study using insurance 
claims data from the Marketscan® Research Databases (2001–2008) enrolled patients 
prior to documented MS (1 inpatient or two outpatient claims with ICD-9-CM 340 
on different days). Enrollment criteria were: 1)brain MRI (index date); 2)at least 1 
MS symptom 6 months prior or 1 month post on non-diagnostic claim; 3)treated 
with DMT post index; 4)no documented MS or DMT during the year prior. Treat-
ment cohorts were Early DMT (DMT claim prior to the ﬁrst documented MS) and 
Delayed DMT (DMT started after documented MS). Comparisons of hospitalizations 
and expenditures during the ﬁrst year of follow-up were adjusted for baseline dif-
ferences between treatment cohorts using inverse probability of treatment –weighted 
(IPTW) regression (general linear model for expenditures and logistic for hospitaliza-
tion). RESULTS: There were 227 (5.7%) Early DMT and 3,724 Delayed DMT. 
Number of days from index until start of DMT therapy was (122 vs. 184, p < 
0.001) for Early vs. Delayed. Hospitalizations were 10.1% vs. 16.5% (Adjusted OR 
0.51, CI: 0.32–0.81). Adjusted per-patient annual expenditures for Early vs. Delayed 
were: Total: ($28,280 vs. $29,102, p = 0.44); Total excluding cost of DMT: ($15,214 
vs. $17,630, p = 0.008), MS-related ($9,365 vs. $13,661, p < 0.001), MS-related 
excluding cost of DMT ($988 vs. $4,907, p < 0.001). CONCLUSIONS: Early treat-
ment with DMT was associated with fewer hospitalizations and lower MS-related 
expenditures. Although overall expenditures were not signiﬁcantly different, 
non-DMT expenditures were lower in the early DMT cohort. This indicates that 
the higher drug expenditures of early treatment with DMT were offset by savings 
in other medical expenditures.
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OBJECTIVES: The objective of this study was to assess the cost-effectiveness of 
Xeomin® compared to placebo in the management of cervical dystonia (CD) and 
blepharospasm (BP) from a Swedish NHS perspective. METHODS: The Country 
Council in Uppsala requested a cost utility analysis (CUA) be performed to assess the 
cost-effectiveness of Xeomin® compared to placebo for the management of CD and 
BP. The economic evaluation uses a Markov model to follow Xeomin® patients 
through six health states of a Markov process in cycle lengths equivalent to the time 
between Xeomin® injections (12 weeks). The duration of the model is 16 cycles (192 
weeks), consistent with the data sources upon which the model is based. The model 
includes six broad variables categories: Xeomin® utilisation and cost; resource utilisa-
tion and unit costs; utility valuation and QALY calculation; discontinuation; adverse 
events and discounting. The structure of the economic evaluation is consistent across 
the two indications. Direct costs were assigned in 16 cycles with the effect on quality-
adjusted life years (QALYs), using data from a prospective, open-labelled cohort 
study. All costs and QALYs accruing after the ﬁrst year of the economic evaluation 
are discounted at 3.0% per annum in accordance with the LFN guidelines. Univariate 
sensitivity analyses were conducted in line with these guidelines. RESULTS: Xeomin® 
was cost-effective versus placebo, with an incremental cost per QALY gained of SEK 
94,317 in CD and SEK 119,182 in BP. Results held under sensitivity analyses. CON-
CLUSIONS: Xeomin® is a cost-effective treatment option relative to placebo for 
patients with CD and BP in Sweden. Xeomin® has the added beneﬁts of i) not requir-
ing cold chain storage, and ii) its potential lower immunogenicity.
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OBJECTIVES: To systematically review pharmacoeconomic evaluations of Rasagiline 
and Entacapone as adjunct therapies in Parkinson’s disease. METHODS: A systematic 
literature search was conducted by one researcher among publications in peer-
reviewed journals from January 2000 to January 2009. Search was conducted using 
Pubmed to identify economic studies that investigated the use of Rasagiline or Enta-
capone in Parkinson’s disease. Key search terms included Rasagiline, Entacapone, 
economic analyses, cost-effectiveness, cost, decision models and various combinations 
of search terms. Economic studies of Rasagiline and Entacapone used as monothera-
pies or in combination with Levadopa were included in the review. Review papers 
were not included in the review. The Quality of Health Economic Studies (QHES) 
instrument ranks the quality of economic studies on sixteen criteria and was utilized 
to assess the comprehensiveness of the economic evaluations. RESULTS: The system-
atic literature search yielded seven studies. Only ﬁve studies met the inclusion criteria. 
One study compared Rasagiline with Pramipexole (payer perspective—NHS, UK), one 
study compared a combination of Rasagiline and Levadopa with Levadopa alone 
(societal and payer), and the remaining studies compared a combination of Enta-
capone and Levadopa with Levadopa alone (societal and payer). All the studies used 
decision models and the analytical time frame ranged from one year to 10 years. 
Outcomes were presented in terms of cost savings and cost/QALYs and were found 
to be below the accepted threshold of $50,000 and 325,000. CONCLUSIONS: The 
economic analyses of Rasagiline and Entacapone demonstrate cost savings and QALY 
gains in Parkinson’s disease. Since the studies are conducted in different countries, 
decision makers have to evaluate the population characteristics, model parameters, 
study assumptions and methodologies in order to make appropriate adjunct therapy 
decisions in Parkinson’s disease.
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OBJECTIVES: To examine the cost-utility of two diagnosis strategies utilizing a 
hypothetical neuroimaging tracer in patients with dementia of Alzheimer type relative 
to a standard diagnosis procedure from a Japanese payer’s perspective. METHODS: 
A cost-utility analysis was performed to evaluate the cost and outcomes associated 
with Dementia of Alzheimer Type (DAT), comparing DAT patients aged over 65 years 
on a standard clinical path to those on a hypothetical Positron Emission Tomography 
(PET) path. A decision tree structure was utilized to simulate follow-up through 20 
years, and a state-transition Markov model was developed to estimate the long-term 
outcomes. Direct medical costs and quality-adjusted life-years (QALYs) were esti-
mated for two diagnosis strategies: 1) PET for all patients, and 2) standard diagnosis. 
Model parameters were derived from the published literature, and National Health 
Insurance data. The model included effectiveness of drug treatment, and costs related 
to the treatment and post-progression care. The model results were examined using 
one-way sensitivity analysis. RESULTS: Preliminary analyses indicate that total 
QALYs for the PET for all, and standard diagnosis strategies were 2.662 and 2.503, 
respectively. Estimated total costs were $23,931, and $21,630, respectively. The 
incremental cost effectiveness ratio (ICER) was estimated to be $14,401 per QALY 
gained. Sensitivity analyses suggest that the most inﬂuential parameters are the accu-
racy of PET tracer, effectiveness of drug treatment, and cost of care. When the 
hypothetical diagnostic drug is assumed to perform as good as standard diagnosis, the 
ICER increases to $97,058 per QALY. CONCLUSIONS: These results suggest that 
the introduction of a PET tracer for this patient population is potentially cost-effective 
by common standards of willingness-to-pay in major developed nations. Ongoing 
efforts are focused on reﬁning model inputs and implementing probabilistic sensitivity 
analysis.
